SG11202006617RA - Combination therapies for the treatment of hepatocellular carcinoma - Google Patents
Combination therapies for the treatment of hepatocellular carcinomaInfo
- Publication number
- SG11202006617RA SG11202006617RA SG11202006617RA SG11202006617RA SG11202006617RA SG 11202006617R A SG11202006617R A SG 11202006617RA SG 11202006617R A SG11202006617R A SG 11202006617RA SG 11202006617R A SG11202006617R A SG 11202006617RA SG 11202006617R A SG11202006617R A SG 11202006617RA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- hepatocellular carcinoma
- combination therapies
- therapies
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862615848P | 2018-01-10 | 2018-01-10 | |
| PCT/US2019/012886 WO2019139977A1 (en) | 2018-01-10 | 2019-01-09 | Combination therapies for the treatment of hepatocellular carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006617RA true SG11202006617RA (en) | 2020-08-28 |
Family
ID=65411938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006617RA SG11202006617RA (en) | 2018-01-10 | 2019-01-09 | Combination therapies for the treatment of hepatocellular carcinoma |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11833119B2 (https=) |
| EP (2) | EP3737377B1 (https=) |
| JP (2) | JP7352569B2 (https=) |
| KR (2) | KR102811519B1 (https=) |
| CN (1) | CN111787922A (https=) |
| AU (1) | AU2019206480A1 (https=) |
| BR (1) | BR112020014112A2 (https=) |
| CA (1) | CA3088292A1 (https=) |
| IL (1) | IL275981A (https=) |
| MA (1) | MA51570A (https=) |
| MX (1) | MX2020007375A (https=) |
| SG (1) | SG11202006617RA (https=) |
| WO (1) | WO2019139977A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023533903A (ja) * | 2020-05-15 | 2023-08-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｆｇｆｒ４阻害剤の経口製剤によるがんの治療方法 |
| CN117479958A (zh) * | 2022-05-30 | 2024-01-30 | 石药集团中奇制药技术（石家庄）有限公司 | 用于治疗癌症的药物组合和药物组合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60137273D1 (de) | 2000-10-20 | 2009-02-12 | Eisai R&D Man Co Ltd | Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten |
| PL1698623T3 (pl) | 2003-12-25 | 2015-08-31 | Eisai R&D Man Co Ltd | Postać krystaliczna soli 4-(3-chloro-4-(cyklopropyloaminokarbonylo)aminofenoksy)-7-metoksy-6-chinolinokarboksamidu lub jej solwatu i sposoby ich wytwarzania |
| RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
| KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| JP2015505562A (ja) * | 2012-01-31 | 2015-02-23 | ノバルティス アーゲー | Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用 |
| KR102265952B1 (ko) | 2013-06-26 | 2021-06-16 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도 |
| MX378288B (es) | 2013-10-18 | 2025-03-10 | Eisai R&D Man Co Ltd | Inhibidores de pirimidina del fgfr4. |
| MX373150B (es) * | 2014-03-26 | 2020-04-21 | Astex Therapeutics Ltd | Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r). |
| US20160089365A1 (en) * | 2014-09-25 | 2016-03-31 | Eisai R&D Management Co., Ltd. | Immunostimulatory compound |
| SG10201810057UA (en) | 2015-04-14 | 2018-12-28 | Eisai R&D Man Co Ltd | Crystalline fgfr4 inhibitor compound and uses thereof |
| CN107304188A (zh) * | 2016-04-20 | 2017-10-31 | 成都融科博海科技有限公司 | 一种氘代激酶选择性抑制剂及其应用 |
| EP3454898B1 (en) * | 2016-05-10 | 2021-11-10 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
-
2019
- 2019-01-09 MA MA051570A patent/MA51570A/fr unknown
- 2019-01-09 EP EP19705261.6A patent/EP3737377B1/en active Active
- 2019-01-09 KR KR1020207022999A patent/KR102811519B1/ko active Active
- 2019-01-09 WO PCT/US2019/012886 patent/WO2019139977A1/en not_active Ceased
- 2019-01-09 AU AU2019206480A patent/AU2019206480A1/en not_active Abandoned
- 2019-01-09 KR KR1020257016389A patent/KR20250073570A/ko active Pending
- 2019-01-09 JP JP2020558858A patent/JP7352569B2/ja active Active
- 2019-01-09 BR BR112020014112-7A patent/BR112020014112A2/pt not_active IP Right Cessation
- 2019-01-09 CA CA3088292A patent/CA3088292A1/en active Pending
- 2019-01-09 MX MX2020007375A patent/MX2020007375A/es unknown
- 2019-01-09 CN CN201980015321.XA patent/CN111787922A/zh active Pending
- 2019-01-09 US US16/961,292 patent/US11833119B2/en active Active
- 2019-01-09 EP EP25207224.4A patent/EP4667005A3/en active Pending
- 2019-01-09 SG SG11202006617RA patent/SG11202006617RA/en unknown
-
2020
- 2020-07-12 IL IL275981A patent/IL275981A/en unknown
-
2023
- 2023-09-15 JP JP2023149903A patent/JP7665700B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200360371A1 (en) | 2020-11-19 |
| US11833119B2 (en) | 2023-12-05 |
| CN111787922A (zh) | 2020-10-16 |
| MX2020007375A (es) | 2020-11-09 |
| JP2023175825A (ja) | 2023-12-12 |
| JP7665700B2 (ja) | 2025-04-21 |
| RU2020126673A (ru) | 2022-02-10 |
| WO2019139977A1 (en) | 2019-07-18 |
| KR20250073570A (ko) | 2025-05-27 |
| KR20200121302A (ko) | 2020-10-23 |
| AU2019206480A1 (en) | 2020-08-27 |
| MA51570A (fr) | 2020-11-18 |
| EP3737377A1 (en) | 2020-11-18 |
| BR112020014112A2 (pt) | 2020-12-01 |
| IL275981A (en) | 2020-08-31 |
| JP7352569B2 (ja) | 2023-09-28 |
| CA3088292A1 (en) | 2019-07-18 |
| EP4667005A2 (en) | 2025-12-24 |
| JP2021512140A (ja) | 2021-05-13 |
| EP3737377B1 (en) | 2025-10-08 |
| KR102811519B1 (ko) | 2025-05-22 |
| EP4667005A3 (en) | 2026-02-18 |
| RU2020126673A3 (https=) | 2022-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| IL276398A (en) | Combined treatment for mastocytosis | |
| SMT202300272T1 (it) | Terapia di combinazione per il trattamento o prevenzione di tumori | |
| SG11201609770TA (en) | Combination therapies for the treatment of cancer | |
| IL267795A (en) | Combined treatment for cancer | |
| IL256224B (en) | Combined therapy for cancer treatment | |
| IL258521A (en) | Combination of treatments for cancer treatment | |
| IL264950B1 (en) | Combined treatments for the treatment of malignant liver cell carcinoma | |
| IL280337A (en) | LAG-3 combination therapy for cancer treatment | |
| IL290955A (en) | Compounds for the treatment of glycogen storage diseases | |
| IL283948A (en) | Methods for treating depression | |
| IL276935A (en) | A therapeutic agent for hepatocellular carcinoma | |
| SG11202103141YA (en) | Combination therapy for the treatment of cancer | |
| EP3624800A4 (en) | TREATMENT OF HEPATOCELLULAR CARCINOMA | |
| IL266993A (en) | Combined therapy for cancer treatment | |
| ZA201904850B (en) | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase | |
| IL284162A (en) | Integrated healing for cancer treatment | |
| IL281997A (en) | Combined treatment for the treatment of uveal melanoma | |
| IL266726A (en) | Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions | |
| SG11202006617RA (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| IL281782A (en) | Drug combination for cancer treatment | |
| IL274747A (en) | FXR agonists for the treatment of liver diseases | |
| IL325751A (en) | Injection techniques for treating cellulite | |
| IL253642A0 (en) | Combined treatment for cancer |